Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Abstract: This invention provides compounds of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; next to R3 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1? secretion.

Abstract: A method for recovering a product mixture from a waste stream in a diaryl carbonate manufacturing process comprising reacting the waste stream with an alkyl alcohol to form a reaction mixture, and separating the product mixture from the reaction mixture.

Abstract: The present invention provides a compound having a formula: where R1 is selected from the group consisting of alkyl, —CH2(OC2H4)OCH3, and —(OC2H4)OCH3; n is 0-4; Olig is an oligomer having a formula: -L-O-PAGR2]q where L is a optional linker moiety selected from the group consisting of —CH2O—, —CH2OX—, —OX—, —C(O)—, —C(O)X, —NH—, —NHC(O)—, —XNHC(O)—, —NHC(O)X—, —C(O)NH—, —C(O)NHX—, and where X is alkyl1-6 or is not present, Y is N or O or is not present, and R3 is alkyl1-6; PAG is a linear or branched polyalkylene glycol moiety; R2 is an alkyl1-22 capping moiety if X is present or alkyl2-22 if X is not present; and q is a number from 1 to the maximum number of branches on PAG; and m is 1-5.

Abstract: The specification provides a method of producing cumene hydroperoxide by continuous aqueous-emulsion oxidation at a high temperature and pressure in a cascade of reactors, wherein the process is conducted in the presence of a mixture of an aqueous solution of an ammonium salt with a concentration of 0.001–0.5 mass % and an aqueous solution of ammonia with a concentration of 0.001–0.5 mass %, which mixture is fed into each oxidation reactor in an ammonia:ammonium salt mass ratio of 1:100 to 100:1.

Abstract: This invention refers to a process for the synthesis of cumene hydroperoxide and to the product thus obtained. More in particular, this invention refers to a process for the production of cumene hydroperoxide by oxidating cumene with oxygen, where this process is run in the presence of a basic medium insoluble in the reaction environment, and such as not to release inorganic cations to the reaction environment. Such a basic medium is preferably a pyridinic resin. The cumene hydroperoxide thus obtained, characterized by the fact of being free of inorganic cations, is a further object of the invention.

Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Abstract: A process for preparing peroxidic perfluoropolyethers having a peroxidic content (PO) higher than 1.2 of formula A-CF2O(CF2CF2O)m(CF2O)n—(CF2CF2OO)ml(CF2OO)nlCF2—B??(I) wherein A, B, equal to or different from each other are Cl—, F—, ClCF2—, COF—, —OCOF, —CF3, m, ml, n, nl are integers such that the (m+ml)/(n+nl) ratio is between 0.9 and 5 and the m/n ratio is between 0.8 and 3, the number average molecular weight is in the range 35,000-45,000, by tetrafluoroethylene (TFE) photooxidation in the presence of UV light, at a temperature from ?80° C. to ?40° C., in the presence of a mixture of solvents formed of HFC-227 (heptafluoropropane) and a solvent selected from HFC-125 (pentafluoroethane) and FC-218 (perfluoropropane).

Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Abstract: The invention provides a process for the removal of polysulfanes from gas streams formed during H2S synthesis.

Abstract: The present invention provides compounds of the Formula I: wherein R1 is alkyl, cycloalkyl, cycloalkylalkyl, or —CH2-alkenyl, X1 is O, NH, N(alkyl), S or —C(?O), Z is N or CH; and R2 and R3 are as defined herein, pharmaceutical compositions comprising same, and methods for their use.

Abstract: Novel trifluoromethanesulfonanilide oxime ether compounds useful for controlling endo and/or ectoparasites in the environment are provided, together with methods of making the same, and methods of using the inventive compounds to treat parasite infestations in vivo or ex vivo.

Abstract: Biphenylcarboxamide compounds of formula (I) methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes.

Abstract: The present invention provides a novel diamine which is especially useful as a material for a resin for a liquid crystal alignment film, a polyimide precursor and a polyimide synthesized by using the diamine, and a treating agent for liquid crystal alignment containing such a polymer, which gives a liquid crystal alignment film having a high pretilt angle of liquid crystal, excellent thermal stability of the pretilt angle and small dependence of the pretilt angle on rubbing pressure. A diaminobenzene derivative represented by the formula (1): wherein X1 and X2 are cyclic groups, and X3 is selected from an alkyl group, an alkoxy group, a fluoroalkyl group, a fluoroalkoxy group, a fluorine atom, a chlorine atom, a bromine atom and a cyano group; a polyimide precursor and a polyimide synthesized by using the diaminobenzene derivative as a part of the material; and a treating agent for liquid crystal alignment containing at least one of the polymers.

Abstract: An object of the present invention is to provide a modified cyclic aliphatic polyamine having a low viscosity and a small content of unreacted polyamine which can provide, when it is used as a curing agent for epoxy resin, an epoxy resin composition having an improved workability without adding solvent or diluent and an excellent property of epoxy resin cure product. The above modified cyclic aliphatic polyamine is obtained by addition reaction of a cyclic aliphatic polyamine such as isophoronediamine and norbornanediamine and an alkenyl compound such as styrene. The modified cyclic aliphatic polyamine thus obtained is added in epoxy resin to be used as a curing agent for epoxy resin.

Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.

Abstract: A process for the autocatalytic production of organic hydroperoxides and ultra low sulfur diesel boiling range hydrocarbons is disclosed. The organic hydroperoxides react with sulfur compounds to produce sulfones, and the sulfones can be removed from the diesel boiling range hydrocarbons to provide ultra low sulfur diesel.

Abstract: Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or modulating ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.

Abstract: The invention relates to intermediate compounds of the formula wherein R1 is H or a protecting group, R2 and R3 each independently represent H, methyl, or a leaving group, provided that at least one, but not both, of R2 and R3 is a leaving group. The intermediate compounds are useful for the synthesis of discodermolide, its derivatives, and related compounds.